



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Atazanavir (Standard)

| | |
|---------------------------|---|
| Cat. No.: | HY-17367R |
| CAS No.: | 198904-31-3 |
| Molecular Formula: | C ₃₈ H ₅₂ N ₆ O ₇ |
| Molecular Weight: | 704.86 |
| Target: | Endogenous Metabolite; Cytochrome P450; P-glycoprotein; HIV Protease; SARS-CoV; HIV |
| Pathway: | Metabolic Enzyme/Protease; Membrane Transporter/Ion Channel; Anti-infection |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | |
|-------------------------------------|---|
| Description | Atazanavir (Standard) is the analytical standard of Atazanavir. This product is intended for research and analytical applications. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration ^[1] . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) ^[2] . Atazanavir is also a SARS-CoV 3CL ^{PRO} inhibitor with an IC ₅₀ of 3.49 μM ^[3] . |
| IC₅₀ & Target | HIV-1 protease ^[1] CYP3A4, P-gp ^[2] |

REFERENCES

- [1]. Havlir DV, et al. Atazanavir: new option for treatment of HIV infection. *Clin Infect Dis*. 2004 Jun 1;38(11):1599-604.
- [2]. Wood R. Atazanavir: its role in HIV treatment. *Expert Rev Anti Infect Ther*. 2008 Dec;6(6):785-96.
- [3]. Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. *Signal Transduct Target Ther*. 2021 May 29;6(1):212.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA